News for Hadasit Bio-Holdings Ltd (HSITF)

Published at

May 5, 2024 3:39 PM

by marketscreener.com

positive

positive

HBL Hadasit Bio : The company has become a "shell company", the sector classification of the company will be changed as of May 7, 2024

PUBT - PHS Attachments Original Link Permalink Disclaimer HBL Hadasit Bio Holdings Ltd. published this...

HSITF HDST.TA

Read more →
Published at

Nov 17, 2022 10:00 AM

by prnewswire.com

negative

negative

Myeloma Investment Fund Invests in KAHR to Explore Potential of KAHR's Lead Immunotherapy Drug Candidate for the Treatment of Multiple Myeloma

/PRNewswire/ -- KAHR, a clinical-stage biotech company developing a novel, bi-specific CD47x4-1BB targeting immunotherapy that activates innate and adaptive...

HSITF HDST.TA

Read more →
Published at

Oct 5, 2022 9:12 PM

by marketscreener.com

mixed

mixed

Enlivex Therapeutics : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS - Form 6-K

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To be held on November 17, 2022 Dear Shareholder: We cordially invite you to attend the Annual... | October 5, 2022

HSITF HDST.TA ENLV.TA ENLV ZIOP VIRX RUBY OPK.TA OPK.MX OPK MRKD.BA MRK.SN MRK.PA MRK.MX MRK MREO MPH.L MCRB KMDA.TA KMDA JNJ INFI FRGAP DJNJ3.BA DJNJ2.BA CFRX 6MK.DE 0KCS.L 0A9G.L

Read more →
Published at

Sep 30, 2021 2:12 PM

by marketscreener.com

mixed

mixed

Enlivex Therapeutics : NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS ON (Form 6-K)

NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS ON NOVEMBER 4, 2021 Notice is hereby given that an Annual and... | September 30, 2021

SPGI HSITF HDST.TA ENLV.TA ENLV ZIOP REDX.L MRK MREO MPH.L KMDA.TA KMDA 0A9G.L

Read more →
Published at

Aug 12, 2021 10:24 PM

by marketscreener.com

positive

positive

Lineage Cell Therapeutics : REPORTs SECOND QUARTER 2021 FINANCIAL RESULTS AND HIGHLIGHTS ADDITIONAL PROGRESS FROM CLINICAL CELL THERAPY PROGRAMS (Form 8-K)

LINEAGE REPORTs SECOND QUARTER 2021 FINANCIAL RESULTS AND HIGHLIGHTS ADDITIONAL PROGRESS FROM CLINICAL CELL THERAPY PROGRAMS ● ... | August 12, 2021

LCTX.TA LCTX HSITF HDST.TA

Read more →
Published at

Jun 16, 2021 12:30 PM

by thestreet.com

positive

positive

KAHR Announces $46.5 Million Financing To Advance Its Multifunctional Immunotherapeutic Pipeline

JERUSALEM, June 16, 2021 /PRNewswire/ -- KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, today announced

HSITF HDST.TA

Read more →

News for Hadasit Bio-Holdings Ltd (HSITF)

HBL Hadasit Bio : The company has become a "shell company", the sector classification of the company will be changed as of May 7, 2024

Myeloma Investment Fund Invests in KAHR to Explore Potential of KAHR's Lead Immunotherapy Drug Candidate for the Treatment of Multiple Myeloma

Enlivex Therapeutics : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS - Form 6-K

Enlivex Therapeutics : NOTICE OF ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS ON (Form 6-K)

Lineage Cell Therapeutics : REPORTs SECOND QUARTER 2021 FINANCIAL RESULTS AND HIGHLIGHTS ADDITIONAL PROGRESS FROM CLINICAL CELL THERAPY PROGRAMS (Form 8-K)

KAHR Announces $46.5 Million Financing To Advance Its Multifunctional Immunotherapeutic Pipeline